It's hard to overstate how much demand could be out there for effective weight management drugs. The global anti-obesity drug ...

While brand-name drugs have a limited window of market ... as well as approval for Omvoh for managing moderately to severely active Crohn’s disease. Eli Lilly and Company (NYSE:LLY)’s rapid ...

Eli Lilly’s Omvoh became the first IL-23 drug approved in ulcerative colitis in October 2023, while AbbVie’s Skyrizi hit the scene as the first IL-23 med cleared by the FDA to treat Crohn’s ...

It's hard to overstate how much demand could be out there for effective weight management drugs. The global anti-obesity drug market is expected to generate $12.8 billion in sales this year, and ...

Other IL-23 inhibitors approved for Crohn's disease include risankizumab (Skyrizi) and mirikizumab (Omvoh). Common adverse events (≥3%) with guselkumab in the Crohn's disease trials included ...

Lilly’s Omvoh was approved for UC in the United States, Europe and Japan in 2023. Omvoh was approved for CD in the United States in January 2025, while applications are under review in Europe ...

as well as approval for Omvoh for managing moderately to severely active Crohn’s disease. Eli Lilly and Company (NYSE:LLY)’s rapid growth in recent years has been largely fueled by the success ...

Yet, unlike its IL-23p19 predecessors — Skyrizi (risankizumab, AbbVie) and Omvoh (mirikizumab, Eli Lilly & Co.) — Tremfya is the only one to demonstrate clinical superiority to the IL-12/23 ...